Magnesium Isoglycyrrhizinate Alleviates Arsenic Trioxide-Induced Cardiotoxicity: Contribution of Nrf2 and TLR4/NF-κB Signaling Pathway
Open Access
- 1 February 2021
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 15, 543-556
Abstract
Purpose: Magnesium isoglycyrrhizinate (MgIG), a single stereoisomer magnesium salt of glycyrrhizic acid, has beneficial effects on the cardiovascular system through anti-inflammatory, anti-oxidation, and anti-apoptotic actions. However, MgIG has not been shown to provide protection against cardiotoxicity induced by arsenic trioxide (ATO). This study aims to demonstrate the protection of MgIG against ATO-induced cardiac toxicity in mice and to investigate the underlying mechanism. Methods: A mouse cardiotoxicity model was established by administering 5 mg/kg ATO for 7 days. MgIG used in conjunction with the ATO to assess its cardioprotection. Results: MgIG administration could significantly reduce reactive oxygen species generation and the changes in tissue morphology. Also, MgIG administration increased the activity of antioxidase, such as superoxide dismutase, catalase, and glutathione peroxidase, and reduced malondialdehyde content and pro-inflammatory cytokine levels. Western blotting showed decreased expression of Bcl-2 associated X protein and Caspase-3, with increased expression of B-cell lymphoma 2. Importantly, MgIG administration increased nuclear factor-erythroid-2-related factor 2 (Nrf2) expression, while the expressions of nuclear factor kappa-B (NF-κB) and toll-like receptor-4 (TLR4) were significantly decreased. Conclusion: Our data showed that MgIG alleviates ATO-induced cardiotoxicity, which is associated to the anti-inflammation, anti-oxidation, and anti-apoptosis action, potentially through activation of the Nrf2 pathway and suppression of the TLR4/NF-κB pathway.Keywords
This publication has 68 references indexed in Scilit:
- Oxidative stress induced by the chemotherapeutic agent arsenic trioxide3 Biotech, 2013
- Salvianolic Acid B Prevents Arsenic Trioxide-Induced CardiotoxicityIn Vivoand Enhances Its Anticancer ActivityIn VitroEvidence-Based Complementary and Alternative Medicine, 2013
- Candidate Genes Expression Profile Associated with Antidepressants Response in the GENDEP Study: Differentiating between Baseline ‘Predictors’ and Longitudinal ‘Targets’Neuropsychopharmacology, 2012
- Dangkwisoo-san, an herbal medicinal formula, ameliorates acute lung inflammation via activation of Nrf2 and suppression of NF-κBJournal of Ethnopharmacology, 2012
- Arsenic Exposure and Toxicology: A Historical PerspectiveToxicological Sciences, 2011
- Subchronic exposure to arsenic trioxide-induced oxidative DNA damage in kidney tissue of miceExperimental and Toxicologic Pathology, 2010
- Arsenic trioxide — An old drug rediscoveredBlood Reviews, 2010
- Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological PreventionJNCI: Journal of the National Cancer Institute, 2010
- Nrf2:INrf2 (Keap1) signaling in oxidative stressFree Radical Biology and Medicine, 2009
- Resveratrol protects against arsenic trioxide‐induced cardiotoxicity in vitro and in vivoBritish Journal of Pharmacology, 2008